Eupraxia Pharmaceuticals (EPRX) Receives a Rating Update from a Top Analyst
In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Eupraxia Pharmaceuticals, with a price target of $16.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Slutsky covers the Healthcare sector, focusing on stocks such as Palvella Therapeutics, Olema Pharmaceuticals, and Oruka Therapeutics. According to TipRanks, Slutsky has an average return of 40.2% and a 51.74% success rate on recommended stocks.
In addition to LifeSci Capital, Eupraxia Pharmaceuticals also received a Buy from Bloom Burton’s David Martin PhD in a report issued on March 18. However, on March 15, TipRanks – OpenAI reiterated a Hold rating on Eupraxia Pharmaceuticals (TSX: EPRX).
Based on Eupraxia Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of C$23.3 million. In comparison, last year the company had a GAAP net loss of C$10.8 million
Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EPRX in relation to earlier this year.
Read More on TSE:EPRX:
Disclaimer & DisclosureReport an Issue
- Eupraxia Pharmaceuticals: Durable EP-104GI Data and Upcoming Catalysts Support Buy Rating
- Eupraxia Pharmaceuticals Posts Strong Six-Month EoE Data for EP-104GI as RESOLVE Trial Advances
- Eupraxia Pharmaceuticals’ esophagitis candidate shows symptom decrease
- Eupraxia price target lowered to $11 from $12 at H.C. Wainwright
- Buy Rating on Eupraxia Pharmaceuticals Driven by EP-104GI’s Differentiated Technology and Favorable Risk‑Reward Profile
